Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Asset / Drug

Risperidone

Drug and asset intelligence for Risperidone with 6 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
4
Catalysts
2
Stage
Development stage unavailable

Sponsor company

Actavis Labs →

Recent signals(4)

RegulatoryAugust 5, 2026

FDA Approves Supplement for Risperidone by Heritage Pharma

The FDA has approved a supplement for the ANDA076228 application for Risperidone submitted by Heritage Pharma.

StrategyJuly 13, 2026

FDA Approval Update for Risperidone by Heritage Pharma

Heritage Pharma has received an Abbreviated New Drug Application (ANDA) approval for Risperidone.

RegulatoryJuly 9, 2026

FDA Accepts Supplement for Risperidone by Actavis Labs

The FDA has accepted a supplemental application for Risperidone submitted by Actavis Labs.

StrategyJune 21, 2026

FDA Grants AP Status for Risperidone ANDA077494 Submission

The FDA has granted an Abbreviated New Drug Application (ANDA) approval status for Risperidone under application number ANDA077494.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts(2)

Topline Data

— Risperidone

July 13, 2026 · N/A

Topline Data

Actavis Labs — Risperidone

July 9, 2026 · N/A

Indications

No related entities indexed yet.

Therapeutic areas

Antipsychotic →
Psychiatry →
Psychiatry · Antipsychotic →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.